Reply  by Bonello, Laurent et al.
O
T
I
S
W
e
d
(
s
s
v
r
r
o
H
fi
n
5
s
p
o
p
t
n
p
c
a
s
a
p
a
t
i
a
w
c
t
l
s
t
b
t
i
t
a
*
A
A
1349JACC Vol. 52, No. 16, 2008 Correspondence
October 14, 2008:1347–51Letters to the Editor*
D
1
P
H
E
R
1
2
3
4
5
6
R
W
(
d
d
u
s
d
T
a
f
t
t
m
p
t
d
s
P
iptimizing Clopidogrel
herapy Before Stent
mplantation: Should Clinical
etting Be Taken Into Account?
e read with great interest the recently published work of Bonello
t al. (1) regarding the clinical benefits of adjusting the loading
ose of clopidogrel prior to percutaneous coronary intervention
PCI) according to platelet reactivity index (PRI) of vasodilator-
timulated phosphoprotein assay. The study is brilliant to demon-
trate that low response to clopidogrel (defined as a PRI 50% in
asodilator-stimulated phosphoprotein assessment) increases the
isk of cardiovascular death and recurrent ischemia. Moreover,
epeated loading doses were successful in 86% of patients to
vercome high PRI that translated to better clinical outcomes.
owever, for the following reasons, implementation of these
ndings to clinical practice is unclear.
The study cohort comprised a mixed population of 46%
on–ST-segment elevation myocardial infarction (NSTEMI) and
4% nonacute coronary syndrome patients. Results of previous
tudies demonstrated that the net clinical benefit of intensifying
latelet inhibition during PCI is highly different between patients
f NSTEMI and stable angina. Likewise, neither clopidogrel
re-treatment nor administration of glycoprotein IIb/IIIa inhibi-
ors (GPI) reduced ischemic complications among troponin-
egative patients scheduled for elective PCI (2,3). Contrarily,
atients admitted with NSTEMI for primary PCI had signifi-
antly lower rates of major adverse cardiac events in cases of GPI
dministration and clopidogrel pre-treatment (4,5). Based on these
tudies, it would be essential to know whether the clinical
dvantages shown in the study were driven by the troponin-
ositive NSTEMI population or whether stable angina patients
lso profited from the repeated loading doses. In a clinical aspect,
here is no time limitation to optimize adenosine diphosphate-
nhibition among stable angina patients before PCI; however, those
dmitted with NSTEMI might be harmed from delays in reperfusion
hile waiting for loading doses to overcome the low response to
lopidogrel (6). As the latter patients might receive immediate GPI
herapy to have proper platelet inhibition, waiting days for repeated
oading doses does not seem the strategy of choice for them.
In conclusion, the landmark study of Bonello et al. (1) demon-
trated in a mixed patient population that optimizing clopidogrel
herapy according to a laboratory assay translates to significantly
etter short-term outcome after PCI. However, it is unclear how
hese results should affect current clinical practice. It seems highly
mportant to separate low-risk stable angina and NSTEMI pa-
ients to be able to draw clear clinical consequences for the best
ntiplatelet strategy before PCI.
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eply
e thank Dr. Aradi and colleagues for their interest in our work
1). Our recently published trial is a pilot study that aimed to
emonstrate that platelet monitoring of response to thienopyri-
ines offers the promise of an improved outcome in patients
ndergoing percutaneous coronary intervention (PCI). Additional
tudies are needed to confirm those preliminary results and to
etermine which strategy of loading dose (LD) should be used.
hus, the present strategy of platelet reactivity (PR) monitoring
nd clopidogrel LD should not be used in clinical practice until
urther validation is reported.
As Dr. Aradi and colleagues highlighted, one potential limita-
ion of the present strategy of clopidogrel LD adjustment is the
ime required to tailor the LD to platelet monitoring. However, it
ust be noted that most patients in the vasodilator-stimulated
hosphoprotein-guided group had PCI after the second LD and
herefore underwent PCI within 48 h of admission. The optimal
elay between clopidogrel LD intakes should be defined by future
tudies to further reduce the time required for adjustment before
CI. Finally, a new P2Y12 adenosine diphosphate receptor that
nduces greater and faster PR inhibition may be particularly
nteresting in those subjects to limit the time required before PCI.
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October 14, 2008:1347–51As stated by Dr. Aradi and colleagues, stable angina or low-risk
cute coronary syndrome patients have a small risk of adverse
vents following PCI. However, reduced thrombotic events still
ccur in such patients. The clinical impact of clopidogrel in these
ow-risk patients is well established and therefore, the lack of
fficacy of the drug may be as critical as in other settings (2,3). In
ddition, the link between PR and recurrent ischemic events after
CI is demonstrated in stable patients similarly to unstable
atients (4). As pointed out by Dr. Aradi and colleagues, the
eri-intervention level of PR inhibition may be more important
han the time of clopidogrel loading. We believe that the teaching
f our study is the clinical impact of a tailored dose of clopidogrel
o obtain a sufficient degree of PR inhibition peri-intervention in
rder to decrease post-procedural thrombotic events. Accordingly,
he number of acute events is low and may offer the possibility of
ost-intervention adjustment (1 acute stent thrombosis). Finally,
he frequency of clopidogrel low response is by far less frequent in
table patients compared with unstable patients, which may
ccount for their reduced rate of events. Furthermore, the low
isk of thrombotic events after PCI may well be a limit to con-
uct specific studies on stable patients that would need a large
umber of patients to be properly powered. Finally, the low
umber of patients included in the present study prevents any
ubgroup analysis to assess the impact of LD adjustment in sta-
le patients.
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biquitin-Proteasome
ystem in the Atherosclerotic
laque Progression
n the May 27, 2008, issue of the Journal, Herrmann et al. (1)
resented atherosclerosis as a protein-quality disease caused by
he accumulation at the vascular level of unfolded/misfolded
roteins linking ubiquitin-proteasome system (UPS) activity to
therosclerotic plaque formation. Although the investigators
aised an interesting scientific concern in this review that the
oss of function for proteins is important in cellular and tissue
unctions, we believe that they present only one side of the dual
ole that the UPS has in vascular lesion formation and plaque
nstability. In our opinion, one should distinguish between the
nitial stage of the plaque formation in which tissue begins to
eact to damaging stimuli (e.g., cell stresses) and the late stage
f plaque characterized by progression of plaque toward desta-
ilization and rupture. In this context, it is conceivable that the
rst stage is characterized by deposition and accumulation of
roteins in cells and tissues when they are produced in large
mounts in response to a noxious stimulus. It is conceivable that
uring this transient stage, the UPS physiologically serves as a
ompensatory circuit acting to avoid low-quality protein aggre-
ations within the endothelium of the vessel walls. This
ypothesis is counteracted by the limited amount of evidence in
umans as well as by the conflicting translation of animal data
o humans. Plaque progression, however, occurs when the
nsufficiency of UPS to degrade the excess of damaged proteins
ecomes a persistently stressful condition for the endothelium.
his leads to progressive accumulation of ubiquitinated pro-
eins, autophagic death, and ultimately to plaque rupture
riggered by a local inflammatory process (2). It is well known
hat an inflammatory process may activate UPS (3), leading to
n overactivity of the system that in turn can develop a vicious
ircle in atherosclerotic vessels. It may further increase inflam-
atory activity through de novo synthesis of the nuclear factor
appa B, which in turn leads to further increments of oxidative
tress and consequently an increase of the ubiquitinated pro-
eins. Indeed, increased UPS activity in plaque macrophage as a
onsequence of the persistent stress may enhance the synthesis
f nuclear factor kappa B in the same cell, possibly representing
crucial step in the pathophysiology of atherosclerosis progres-
ion toward instability. Nevertheless, these are only hypotheses.
pecific clinical studies evaluating the effect of an intervention
o selectively modulate the UPS, in relation to the stage of
isease, are the only ones able to give a definite answer to the
uestion whether an increase and/or a decrease in UPS activity
ay be responsible for atherosclerosis progression.
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